Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 May 1;32(5):265.
doi: 10.3390/curroncol32050265.

Patient-Reported Outcome Measures (PROMS) in Lymphoma

Neha Akkad  1 , Christopher R Flowers  2
Affiliations

Patient-Reported Outcome Measures (PROMS) in Lymphoma

Neha Akkad et al. Curr Oncol. .

Abstract

Patient-reported outcome measures (PROMs) are often used to evaluate the impact of treatment and clinical decisions on the patient experience for patients with lymphoma. Regulatory agencies have provided guidance on the use of PROMs for patient-focused drug development. Though PROMs are increasingly utilized, the way in which they are used, analyzed, and reported is heterogeneous. This systematic evidence-based review will focus on how PROMs are currently used for patients with lymphoma, what domains PROMs measure, their clinical significance, links to clinical outcomes, and what gaps need to be filled to better incorporate PROMs as endpoints in clinical trials and clinical decision-making.

Keywords: lymphoma; patient-reported outcomes; quality of life.

PubMed Disclaimer

Conflict of interest statement

C.R.F. has served as a consultant for AbbVie, Bayer, BeiGene, Celgene, Denovo Biopharma, Foresight Diagnostics, Genentech/Roche, Genmab, Gilead, Karyopharm, N-Power Medicine, Pharmacyclics/Janssen, SeaGen, and Spectrum; holds stock or stock options for Foresight Diagnostics and N-Power Medicine; and has received research funding from 4D, AbbVie, Acerta, Adaptimmune, Allogene, Amgen, Bayer, BostonGene, Celgene, Cellectis EMD, Gilead, Genentech/Roche, Guardant, Iovance, Janssen Pharmaceutical, Kite, Morphosys, Nektar, Novartis, Pfizer, Pharmacyclics, Sanofi, Takeda, TG Therapeutics, Xencor, and Ziopharm, as well as Burroughs Wellcome Fund, Cancer Prevention and Research Institute of Texas RR190079: CPRIT Scholar in Cancer Research; Eastern Cooperative Oncology Group, National Cancer Institute, and V Foundation. All the other authors declared that they have no conflicts of interest to declare.

Similar articles

See all similar articles

References

    1. Basch E., Jia X., Heller G., Barz A., Sit L., Fruscione M., Appawu M., Iasonos A., Atkinson T., Goldfarb S., et al. Adverse symptom event reporting by patients vs clinicians: Relationships with clinical outcomes. J. Natl. Cancer Inst. 2009;101:1624–1632. doi: 10.1093/jnci/djp386. - DOI - PMC - PubMed
    1. Fromme E.K., Eilers K.M., Mori M., Hsieh Y.C., Beer T.M. How accurate is clinician reporting of chemotherapy adverse effects? A comparison with patient-reported symptoms from the Quality-of-Life Questionnaire C30. J. Clin. Oncol. 2004;22:3485–3490. doi: 10.1200/JCO.2004.03.025. - DOI - PubMed
    1. Marino D., Baratelli C., Guida G., Turco C.G.C., Lacidogna G., Sperti E., Vignani F., De Luca E., Zichi C., Audisio M., et al. Impact of adoption of patient-reported outcomes in clinical practice on the accuracy of symptom reporting in medical records of cancer patients. Recent. Progress. Med. 2020;111:740–748. doi: 10.1701/3509.34965. - DOI - PubMed
    1. Basch E., Iasonos A., McDonough T., Barz A., Culkin A., Kris M.G., Scher H.I., Schrag D. Patient versus clinician symptom reporting using the National Cancer Institute Common Terminology Criteria for Adverse Events: Results of a questionnaire-based study. Lancet Oncol. 2006;7:903–909. doi: 10.1016/S1470-2045(06)70910-X. - DOI - PubMed
    1. Oerlemans S., Arts L.P., Horevoorts N.J., van de Poll-Franse L.V. “Am I normal?” The Wishes of Patients with Lymphoma to Compare Their Patient-Reported Outcomes with Those of Their Peers. J. Med. Internet Res. 2017;19:e288. doi: 10.2196/jmir.7079. - DOI - PMC - PubMed

Publication types

LinkOut - more resources